(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 March 2008 (06.03.2008)

PCT

(10) International Publication Number
WO 2008/027013 A2

(51) International Patent Classification:
A61K 31/436 (2006.01) *A61K 45/06* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/SG2007/000191

(22) International Filing Date: 29 June 2007 (29.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/840,904 29 August 2006 (29.08.2006) US

(71) Applicant *(for all designated States except US)*: **NATIONAL CANCER CENTRE** [SG/SG]; 11 Hospital Drive, Singapore 169610 (SG).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HUYNH, The Hung** [CA/SG]; c/o National Cancer Centre, 11 Hospital Drive, Singapore 169610 (SG). **CHOW, Pierce, Kah-Hoe** [MY/SG]; c/o National Cancer Centre, 11 Hospital Drive, Singapore 169610 (SG). **SOO, Khee Chee** [MY/SG]; c/o National Cancer Centre, 11 Hospital Drive, Singapore 169610 (SG).


(74) Agents: **FOO, Moo Kwang** et al.; Axis Intellectual Capital Pte Ltd, 21A Duxton Road, Singapore 089487 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: COMPOSITION AND METHOD



(57) Abstract: We provide a composition comprising a first agent which is an antagonist of mTOR activity, together with a second agent comprising an angiogenesis inhibitor. The first agent may comprise rapamycin, and the second agent may comprise an inhibitor of VEGF activity such as Bevacizumab (Avastin). Such a composition may be used for preventing the growth or proliferation, or both, of a cell or tissue. The composition may also be used to treat or prevent cancer, such as hepatocellular carcinoma (HCC).

WO 2008/027013 A2

FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*